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2Abstract
The cytosolic acyl-CoA thioesterase I (Acot1) is an enzyme that hydrolyzes long-
chain acyl-CoAs of C12-C20-CoA in chain-length, to the free fatty acid and
coenzyme A. Acot1 was previously shown to be strongly upregulated at mRNA
and protein level in rodents by fibrates. In this study, we show that Acot1 mRNA
levels were increased 90-fold in liver by treatment with Wy-14,643 and that
Acot1 mRNA is also increased 15-fold in the liver of hepatocyte nuclear factor 4
alpha (HNF4a) knockout animals. Our study identified a direct repeat 1 (DR1)
located in the Acot1 gene promotor in mouse, which binds the peroxisome
proliferator-activated receptor alpha (PPARa) and the HNF4a . Chromatin
immunoprecipitation assay (ChIP) showed that the identified DR1 bound
PPARa/retinoid X receptor alpha (RXRa) and HNF4a, whereas the binding in
ChIP was abrogated in the PPARa  and HNF4a  knockout mouse models.
Reporter gene assays showed activation of the Acot1 promotor in cells by the
PPARa agonist Wy-14,643, following co-transfection with PPARa/RXRa.
However, transfection with a plasmid containing HNF4a also resulted in an
increase in promotor activity. Taken together, these data show that Acot1 is
under regulation by an interplay between of HNF4a and PPARa.
Key words: peroxisome proliferator response element, direct repeat 1, acyl-CoA,
lipid metabolism.
3Introduction
Nuclear receptors are ligand-activated transcription factors that regulate the
expression of a myriad of genes by binding to specific DNA elements. One
example is the peroxisome proliferator-activated receptor alpha (PPARa), a
nuclear receptor identified in 1990 by Issemann and Green, which at that time
was shown to be activated by peroxisome proliferators (1). The PPARa is
involved in the transcriptional control of numerous genes involved in b-
oxidation of fatty acids in mitochondria and peroxisomes, bile acid metabolism
and inflammation control (for review see (2)), lipoprotein metabolism (3),
glycerol metabolism (4) and amino acid metabolism (5). Targeted disruption of
the PPARa in mouse by Lee et al in 1995 substantiated the role of this nuclear
receptor in regulation of lipid homeostasis (6). The binding of the PPARa as a
heterodimer with the retinoid X receptor (RXR) to a direct repeat 1 (DR1) element
(AGGTCAnAGGTCA or variants thereof) in the promotor/intron of target genes
has now been widely established (2). Studies on endogenous ligands for the
PPARa showed that this nuclear receptor is activated by a variety of free fatty
acids such as linoleic acid, linolenic acid and arachidonic acid, but also weakly
activated by saturated long chain fatty acids (7-9). More recently, acyl-CoAs, the
activated form of fatty acids, were also shown to activate the PPARa (10). Thus
the intracellular levels of acyl-CoAs and free fatty acids are important in
regulation of this nuclear receptor. This DR1 element that binds the PPARa/RXR
heterodimer can also bind another nuclear receptor, the hepatic nuclear factor 4
alpha (HNF4a) as a homodimer (11). The HNF4a (NR2A1) is expressed in liver,
kidney, intestine and pancreas (12) and is central to maintenance of hepatocyte
differentiation and regulation of genes involved in lipid metabolism (13). The
ligands for HNF4a are shown to be various acyl-CoA esters, which act as
agonists/antagonists, depending on the chain-length and degree of saturation
(14).
Interestingly, there is a family of enzymes that hydrolyze acyl-CoAs to the free
fatty acid and coenzyme A, and acyl-CoAs/free fatty acids act as either
4agonists/antagonists for the PPARa and the HNF4a. These enzymes are called
acyl-CoA thioesterases (Acots) (for review see (15)), and a new nomenclature
was recently introduced (16). One member of this gene family, the cytosolic acyl-
CoA thioesterase I (Acot1, but previously known as CTE-I) was identified as a
peroxisome proliferator-induced enzyme in rodent liver (17-20).
The Acot1 cDNA was initially cloned from rat (21) and was shown to be induced
in liver by the peroxisome proliferator di(2-ethylhexyl) phthalate (DEHP) (22). At
the same time, the cDNA (17) and gene (19) was cloned from mouse and was also
shown to be induced by the peroxisome proliferator clofibrate in liver at both
mRNA and protein level (18,19). The Acot1 is mainly expressed in liver, kidney,
heart and lung and is upregulated by fasting in kidney (18). Acot1 is also
strongly upregulated by fasting in liver and heart, in a partly PPARa -
independent manner (18), and upregulated under diabetic conditions in rat liver
(23). Although it has been shown that Acot1 is upregulated by fibrates and
fasting via the PPARa, an actual peroxisome proliferator-response element has
not been identified. In this study, we identify the response element involved in
activation of Acot1 by PPARa/RXRa. The response element located between
–9600 bp and –9612 bp upstream of the translation start site ATG in Acot1 bound
to the PPARa/RXRa in-vivo and in-vitro, and was activated in a cell system in
the presence of Wy14,643, a PPARa ligand. Interestingly, the same DR1 element
also bound HNF4a resulting in a slight increase of promotor activity. In vivo, the
Acot1 mRNA was induced 15-fold in HNF4a knockout mouse, suggesting that
Acot1 may be regulated by HNF4a. Our data show that Acot1 is regulated by a
delicate interplay between PPARa/RXRa and HNF4a.
Materials and Methods
Identification of a DR1 in the promotor of the Acot1 gene
The gene structure of the mouse Acot1 had previously been identified from a P1
clone purchased from Genome Systems Inc (19). Approximately 6 kb of the
genomic sequence of Acot1 upstream of the ATG start site was sequenced from
5this phage clone. This 6 kb sequence was used to blast against the mouse
genomic sequence (www.ncbi.nlm.nih.gov) to obtain the full sequence of the
Acot1 promotor region. Computer assisted and visual analysis was used to
identify putative response elements.
Animals and treatment
Liver was excised from male HNF4a floxed (F/F) and HNF4a knockout mice
(HNF4a DL) aged between 45-56 days as described (13). Ten to twelve-week old
wild-type or PPARa-null male mice on a pure Sv/129 genetic background were
treated for 1 week with 0.1% (w/w) Wy-14,643 (Calbiochem-Novabiochem
International) as described previously (24). Animals were sacrificed by CO2
asphyxiation followed by cervical dislocation and liver was excised and stored at
–70ºC for preparation of total RNA. All studies were carried out with ethical
permission from the Animal Ethics Board, Stockholm, Sweden.
Reporter gene assay constructs
Two constructs in the 5’-flanking region of mouse Acot1, containing the putative
DR1, were constructed by PCR from a genomic P1 clone containing the Acot1
g e n e  ( 1 9 ) ,  u s i n g  t h e  f o l l o w i n g  p r i m e r s
C T C G A G C A G A C T T G A A G G C A G A T G G T T T - 3 ’  a n d  5 ’ -
C T C G A G TTTTTCTTCCTTGTGTTGTAATCC-3’ (1,861 bp) and 5’-
C T C G A G C A C C G G A G T C A C C T G A T A G A G T C - 3 ’  a n d ,  5 ’ -
CTCGAGGCCAGGGTGCACAGACTTT-3’ (157 bp) with the XhoI sites
indicated in bold. The first construct was 1,861 bp in length and corresponded to
bp -8659 to -10,520 upstream of the ATG start site in the Acot1 gene. A shorter
construct of 157 bp in length was also generated and corresponded to –9506 to
–9663 upstream of the ATG start site. The PCR was performed as follows: 94°C
for 30 sec, 61°C for 30 sec, 72°C for 3 min (or 1 min for 157 bp) and 72°C for 10
min. The PCR products were cloned into the luciferase reporter vector pGL3
Promotor (constructs named pGL3-Acot1-1861 and pGL3-Acot1-157). Sequences
were verified using the ABI Prism Dye Terminator Ready-Reaction Kit (Perkin
Elmer). Mutations were introduced into the DR1 element using Quikchange™
site directed mutagenesis kit (Stratagene, La Jolla) according to the
6Manufacturer’s instructions, using 16 cycles. The primers used were
GGGCTGAGTTGGAACTGGGTTTAAAAACATGGCAAGCTCTC (and the
reverse complement primer) with the mutated bases underlined in italics
(constructs named pGL3-Acot1D1861 and pGL3-AcotD157). The PPARa  and
RXRa plasmids were as described previously (24) and the HNF4a in pCMV (25)
was a kind gift from Dr John Chiang.
Chromatin Immunoprecipitation Assay (ChIP)
Freshly isolated livers were ground to a fine powder under liquid nitrogen and
crosslinked in 1% formaldehyde in 1 X phosphate buffered saline (PBS) at 37ºC
for 20 min.  Crosslinking was terminated with 0.125 M glycine and the cell pellet
was washed twice with 1 X PBS. Nuclei were isolated and lysed in an SDS lysis
buffer (50 mM Tris-HCl pH 8.1, 10 mM EDTA, 1% SDS, and protease inhibitors).
Chromatin were sheared by sonication and the nuclei lysate was cleared by
centrifugation at 50,000 x g for 30 min. The soluble chromatin was diluted 10-fold
(0.01% SDS, 1.1% Triton X 100, 1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.1, and 167
mM NaCl) and immunoprecipitated with primary antibody for PPARa (Geneka)
or HNF4a (K2915 ABcam). The antibody/protein/DNA complex was isolated
using magnetic beads conjugated with protein A (New England Biolabs).
Following several washes the protein/DNA complex was eluted (50 mM
NaHCO3, 1% SDS) from the magnetic beads and crosslinking was reversed by
incubation at 65ºC overnight. The samples were incubated with proteinase K for
1 hour at 45ºC, and following protein digestion the DNA was purified using
phenol/chloroform/isoamyl alcohol extraction, and 2-5 mL of sample was used
for PCR. The PCR was performed for 31 cycles as follows: 94ºC for 3 mins,
followed by 94ºC for 30 sec, 56ºC for 30 sec and 72ºC for 1 min, followed by 72ºC
for 7 min.  Primers used were Acot1 DR1 forward 5’-
C A C C G G A G T C A C C T G A T A G A G T C - 3 ’  a n d  r e v e r s e  5 ’ -
GCCAGGGTGCACAGACTTT-3’ amplifying an area of 157 bp (~9.6kb upstream
of the ATG start site) containing the DR1. The ChIP negative primers amplified
an area of 141 bp located ~1.8kb upstream of the ATG start methionine, which
does not contain any DR1. PCR products were resolved on a 2% agarose gel.
7Cell culture and transfections
HepG2 cells were routinely cultured in EMEM (Sigma Corp), L-glutamine, 10%
fetal bovine serum, penicillin/streptomycin (100U/ml of each) in an atmosphere
of 5% CO2. HeLa cells were cultured in EMEM (Sigma Corp) with 10% fetal
bovine serum, 1mM sodium pyruvate, 1% non-essential amino acids and
penicillin/streptomycin (100U/ml of each) in an atmosphere of 5% CO2. The cells
were cultured in 24 well plates and grown to approx. 70% confluence before
transfection. The transfections were carried out using Tfx-20 reagent (Promega
Corp.), in a ratio of 1:2 (v/v) plasmid to reagent. Cells were transfected with 0.25
mg Acot1 promotor plasmids pGL3-Acot1-1861 and pGL3-Acot1D1861 or pGL3-
Acot1-157 and pGL3-Acot1D157, 0.25 mg of the PPARa , RXRa  or HNF4a
expression vectors and 0.3 mg of the pSV-b-galactosidase control vector. DNA
concentrations were kept constant using pcDNA3.1(+) (empty vector) where
appropriate. Twenty four hours post-transfection, the cells were treated with 50
mM Wy-14,643 or dimethyl sulfoxide (DMSO) as vehicle where appropriate, as
indicated in the figure legends. Cell lysates were assayed for luciferase activity
using Luciferase Reporter Gene Assay (Promega Corp.) and for b-galactosidase
activity using b-Galactosidase Enzyme Assay System (Promega Corp.).
Experiments were carried out in triplicate wells and two to four individual
experiments were carried out. Luciferase activity was normalized to b-
galactosidase activity.
Electromobility shift assay
Oligonucleotides (Cybergene AB, Huddinge, Sweden) corresponding to the DR1
f o r  t h e  m o u s e  A c o t 1 w e r e  a s  f o l l o w s :  5 ’ -
gctgagttggaactGGGGCAAAGTTCAtggcaagctct-3’, (plus the reverse complement
primer) with the core sequence of the DR1 site indicated in capitals. Mutated
DR1 oligos were also used with the mutations underlined in italics: 5’-
gctgagttggaactGGGTTTAAAAACAtggcaagctct-3’. 10 pmol of each primer was
annealed to give double stranded probes and labeled with g-32P ATP
(Amersham Biosciences) using T7 polynucleotide kinase (Promega Corp). In vitro
8translated PPARa, RXRa and HNF4a were synthesized using the TNT coupled
reticulocyte lysate system (Promega Corp., Madison, WI). Gel mobility shift
assay incubation mixes (25 ml) contained 10 mM Tris (pH 7.8), 20 mM KCl, 2 mg
bovine serum albumin (BSA), 10% glycerol, 500 ng of poly(dI-dC).poly(dI-dC)
(Pharmacia Biotech) and 1 ml of in-vitro translated PPARa, RXRa or HNF4a.
Competition experiments were performed with 50-fold molar excess of unlabeled
specific probes and supershift was carried out using an RXRa antibody (a kind
gift from Dr. Pierre Chambon) or a HNF4a antibody (Ab. HNF4a (C19)X, Santa
Cruz Biotechnology, Inc.) as indicated in figure legends. 50,000 cpm of labeled
probe was added to each reaction and incubated on ice for 45 minutes. The
complexes were resolved on a 5% polyacrylamide gel in 1X Tris Borate EDTA
(TBE) and the gel was dried and exposed to X-ray film.
Real-time PCR
Total RNA was prepared from the livers of four male HNF4a floxed (F/F) and
four HNF4a knockout mice (HNF4a DL) aged between 45-56 days as described
(13), using Trizol Reagent (Invitrogen Corp.). Ten to twelve-week old wild-type
or PPARa-null male mice on a pure Sv/129 genetic background were treated for
1 week with 0.1% (w/w) Wy-14,643 (Calbiochem-Novabiochem International) as
described previously (24). Total RNA was isolated from liver samples using
QuickPrep® Total RNA extraction Kit (Amersham Biosciences) and DNase
treated using RNeasy Protect (Qiagen). Mouse Acot1 specific PCR primers and
probe (forward primer: 5’CTGGCGCATGCAGGATC-3’, reverse primer: 5’-
GGCACTTTTCTTGGATAGCTCC-3’, 5’-FAM-labeled TaqMan TAMRA probe:
5’TGGGTTCAATCCAGCTGCGAGAAATAAAG-3’ were designed in the 3’-
untranslated region of the Acot1 gene using the Primer Express Software
(Applied Biosystems). 1 mg of total RNA from each liver sample was reverse
transcribed into cDNA using iScript (Biorad Inc.). The PCR amplifications were
performed in triplicate using TaqMan Universal PCR Master Mix (Applied
Biosystems). The relative amount of Acot1 mRNA was quantified in liver tissue
using single-plex real time PCR analysis in an ABI PRISM® 7000 Sequence
Detection System, using eukaryotic 18S rRNA as an endogenous control
9(Applied Biosystems). The average Ct value per treatment was used to calculate
relative expression levels of mouse Acot1 mRNA with the DDCT method.
Results
The Acot1 is regulated by fibrate treatment via PPARa  in-vivo.
It has previously been shown that Acot1 is upregulated at mRNA and protein
level in rodents by treatment with clofibrate (17-19) and DEHP (21). However,
this upregulation at mRNA level was shown only by Northern blot analysis and
to quantitatively examine the level of induction of Acot1 mRNA in mouse liver
by Wy-14,643, real-time PCR was carried out, using specific primers towards
Acot1. The Acot1 was upregulated 90-fold in mouse liver following Wy-14,643
treatment, whereas this upregulation was not evident in the PPARa-null
animals, showing that the regulation of Acot1 by fibrates is PPARa-dependent
(Fig. 1). To confirm that treatment of the animals with Wy-14,643 was successful,
the upregulation of acyl-CoA oxidase, a well-known PPARa target gene has
previously been shown for the same RNA samples (24).  Notably, the Acot1 basal
mRNA level was doubled in the PPARa-null animals.
Identification of a DR1 in the Acot1 gene promotor
Acot1 is very highly induced in mouse liver by fibrate treatment, however the
actual peroxisome proliferator-response element in the Acot1 gene has not been
identified. We had previously sequenced 6 kb of the promotor region using
conventional sequencing from a P1 clone known to contain the Acot1 gene (19).
However, this area contained only one putative PPRE approx. 2 kb upstream of
the translation start site, which was tested using reporter gene systems and
EMSA and was not functional (data not shown). The transcription start site is
considered to be about 9 nucleotides upstream of the ATG translation start site in
Acot1 (19). The availability of the complete mouse genomic sequence enabled us
to obtain the Acot1 promotor sequence and identify an imperfect direct repeat 1
(DR1) between –9600 bp and –9612 upstream of the ATG start site (Fig. 2). This
DR1 was a good candidate to be a PPRE, as DR1 elements have been shown to
bind to the heterodimer partnership PPARa/RXRa. It has also been shown that
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the 7 nucleotides in the 5’ flanking region of identified PPREs have an important
influence on binding of the PPARa (26). Notably, 5 out of the 7 bp in the 5’-flank
of the DR1 element of the Acot1 promotor were conserved, strongly suggesting
that this could be a candidate for a functional PPRE.
The DR1 in the Acot1 promotor is activated by Wy-14,643.
To evaluate whether the identified DR1 in the Acot1 promotor could be activated
by PPARa ligands in a cell system, promotor constructs were generated in the
pGL3 promotor vector, containing an endogenous SV40 promotor. This vector
was used to clone fragments of the Acot1 promotor region containing the DR1.
One plasmid contained a 1,861 bp fragment of the Acot1 promotor region from
–8659 to –10,520 upstream of the ATG translation start site, containing the DR1
(pGL3-Acot1-1861) and a further plasmid contained a mutated DR1 (pGL3-
Acot1D1861). Cotransfection of these plasmids was carried out together with
plasmids containing the PPARa and RXRa  as described in Materials and
Methods. The activity of the pGL3-Acot1-1861 promotor construct in HepG2 cells
was not increased by Wy-14,643 treatment in the absence of transfected
PPARa/ R X R a  (Fig. 3A). However, following co-transfection with
PPARa/RXRa, the promotor activity was increased significantly in the presence
of PPARa/RXRa alone (p<0.001). Addition of Wy-14,643, a PPARa ligand,
resulted in a further increase in promotor activity (p<0.001 – pcDNA3.1 + Wy-
14,643 vs PPARa/RXRa + Wy-14,643). A construct containing two copies of the
acyl-CoA oxidase PPRE (AOx-tk-Luc) was used as a positive control (27) which
showed an induction by PPARa/RXRa + Wy-14,643 (p<0.001) similar to that
observed in the Acot1 native promotor (Fig. 3A).  We also introduced mutations
into the Acot1 DR1 (pGL3-Acot1D1861) to abolish binding of the PPARa/RXRa
heterodimer. Transfection of HepG2 cells with the wild-type pGL3-Acot1-1861
vector resulted in a significant increase in promotor activity in the presence of
PPARa/RXRa + Wy-14,643, however mutation of the DR1 site abolished this
activation (Fig. 3B), confirming that the identified DR1 is responsible for
activation by PPARa/RXRa.
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The Acot1 DR1 binds PPARa/RXRa in-vivo and in-vitro
To determine if the DR1 identified at –9,600 to -9612 in the Acot1 promotor could
bind directly to PPARa/RXRa, both ChIP and electromobility shift assay
(EMSA) were carried out. ChIP assay was carried out using wild-type and
knockout animals for PPARa (6,13), whereas EMSA was carried out using in-
vitro translated PPARa/RXRa as described previously (24).
ChIP resulted in the binding of PPARa to the Acot1 DR1 identified in wild-type
mouse liver extract, and the binding was increased by treatment with Wy14,643
(Fig. 4A upper panel). In the PPARa-null mouse liver extract, no binding to the
Acot1 DR1 was evident, showing that the DR1 binds to PPARa in-vivo. As a
negative control, primers amplifying an area of Acot1 promotor (~1.8kb
upstream of the ATG start site) not containing the DR1 showed no binding by
PPARa in either wild-type or knockout liver nuclei (Fig. 4A lower panel).  Using
EMSA, neither PPARa nor RXRa bound to the Acot1 DR1 element individually,
however, in the presence of both PPARa and RXRa, there was a strong binding
to the Acot1 DR1, showing that this element can bind directly to this heterodimer
partnership (Fig. 4B). Addition of 50-fold molar excess of cold Acot1 probe
competed out the binding of the g-32P labeled Acot1 probe and supershift was
evident in the presence of the RXRa antibody, confirming that the complex
identified by EMSA contains the RXRa. Mutations introduced into the DR1
abolished binding by PPARa/RXRa to the DR1 or any supershift by the RXRa
antibody (Fig. 4B). The lack of binding to the mutated DR1 in EMSA also
substantiates the lack of induction of promotor activity of pGL3-Acot1D1861 in a
cell system (Fig. 3B).
The Acot1 promotor is regulated by HNF4a
The HNF4a  also binds to a DR1 sequence and we therefore examined the
possible involvement of this receptor in control of Acot1 expression. Transfection
of HepG2 cells with empty pGL3 promotor vector in the presence of HNF4a
12
resulted in a significant downregulation of promotor activity (the vector contains
an endogenous SV40 promotor), and therefore this system was not suitable for
further experiments with HNF4a. Therefore HeLa cells were used for further
experiments with HNF4a. As a positive control, a plasmid expressing the
promotor of the hepatic ornithine transcarbamylase (OTC) gene in pGL3 Basic
(OTC-235-Luc) was used (28), which was upregulated 2.5 fold by transfection
with HNF4a  in HeLa cells. Acot1 promotor activity (pGL3-Acot1-157) was
doubled by co-transfection with HNF4a , however mutation of the DR1 in pGL3-
Acot1D150 abolished the upregulation via HNF4a (Fig. 5A). This data identifies
that the Acot1 promotor is upregulated by HNF4a.
To assess if HNF4a could compete for binding to the DR1 identified, in the
presence of PPARa/RXRa, HeLa cells were transfected with PPARa/RXRa and
treated with Wy-14,643, in the presence of varying amounts of HNF4a. The
Acot1 promotor construct pGL3-Acot1-157 was activated in the presence of
PPARa/RXRa + Wy-14,643 (similar to that seen with pGL3-Acot1-1861 in
HepG2 cells), whereas this activity was reduced significantly in the presence of
0.25 mg HNF4a and further reduced by transfection with 0.5 mg HNF4a (Fig. 5B).
The mutated Acot1 promotor pGL3-Acot1D157 also showed a very slight
downregulation of promotor activity in the presence of co-transfected HNF4a,
however this was similar to that seen in the empty pGL3 promotor vector.
The Acot1 promotor binds to HNF4a in-vivo and in-vitro.
ChIP and EMSA were also carried out on the same DR1 element using liver
extracts from HNF4a floxed and knockout animals, and in-vitro translated
HNF4a. ChIP confirmed the in-vivo binding of HNF4a  to the same DR1 element
in the Acot1 promotor as the PPARa and the specificity of this was again
confirmed using liver extracts from the HNF4a knockout mouse (Fig. 6A),
although some weak signal was detected in the knockout liver extracts. This may
be due to the fact that the HNF4a is a conditional liver specific knockout and
there is some very low amount of HNF4a protein present in the nucleus (29).
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EMSA was also performed using in-vitro translated HNF4a and binding to the
DR1 was competed using 50-fold molar excess cold probe and supershifted using
a HNF4a antibody (Fig. 6B). Mutation of the DR1 element abolished binding of
the HNF4a or any supershift by the HNF4a antibody. These results confirm the
identification of a DR1 element in Acot1 that can bind both PPARa/RXRa and
HNF4a in-vivo and in-vitro.
As the promotor of Acot1 was regulated by HNF4a in HeLa cells, and both ChIP
and EMSA confirmed binding of the HNF4a to the DR1 identified, it seemed
likely that Acot1 is regulated by HNF4a in liver. The Acot1 mRNA levels in the
livers of HNF4a knockout were therefore investigated. Real-time PCR showed
that Acot1 mRNA levels were upregulated 15-fold in the HNF4a knockout
mouse model, indicating that Acot1 mRNA expression is affected by loss of
HNF4a expression in liver (Fig. 6C).
Discussion
We have shown in this study that the Acot1 is a target gene of both the PPARa
and HNF4a using animal models, ChIP and reporter gene assays. The Acot1 is
positively regulated by PPARa, through a direct binding to a DR1 element
located in the distal promotor. Interestingly this DR1 also binds to HNF4a and
results in an upregulation of Acot1 promotor activity. The binding of both these
receptors to the Acot1 DR1 element is intriguing and ChIP shows that this
element can be occupied by either nuclear receptor in-vivo. Most likely,
competition between these two receptors can regulate transcription of the Acot1
gene, either at basal level or during perturbed lipid metabolism (fibrate
treatment or fasting – (this study and (17,18,23)). The basal level of Acot1 mRNA
is doubled in the liver of the PPARa knockout mouse (Fig. 1), indicating that the
Acot1 promotor is under slight repression by PPARa/RXRa in the fed state.
Hayhurst et al showed that the expression of PPARa mRNA is downregulated in
the HNF4a knockout mouse (13), which may therefore result in a consequent
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upregulation of Acot1 in the HNF4a knockout (due to lower expression levels of
PPARa). However considering that Acot1 mRNA is only doubled in response to
complete loss of PPARa, the reduced level of PPARa in the HNF4a knockout
mouse could not account for the corresponding induction of Acot1 mRNA in the
HNF4a-null mice (15-fold) and therefore is more likely a consequence of the loss
of HNF4a. The HNF4a null mouse model shows altered lipid homeostasis, with
a number of genes showing decreased transcription and others increased
transcription as a consequence of the loss of HNF4a (13). The scavenger receptor
class B type 1 (SR-BI), medium chain acyl-CoA dehydrogenase (MCAD),
carnitine palmitoyl transferase II (CPT-II) and 3-hydroxy-3-methyl-glutaryl
coenzyme A synthase (HMG-CoA synthase) were upregulated in the livers of
HNF4a mice and interestingly the three latter genes are all PPARa target genes.
As steady-state levels of PPARa mRNA are decreased in the livers of the HNF4a
knockout, but some PPARa target genes are still upregulated, it was suggested
that increased concentrations of PPARa ligands in the form of free fatty acids,
may account for these effects (13). Our study identifies that Acot1 is another
PPARa target gene that is increased in the livers of HNF4a-null mice. As the
Acot1 can hydrolyze acyl-CoAs to free fatty acid and CoA, it is tempting to
speculate that the upregulation of Acot1 in the HNF4a knockout could regulate
levels of ligands for the PPARa and HNF4a in the form of free fatty acids or acyl-
CoAs. Although the specific function for Acot1 has not been fully resolved, the
hypothesis is that this enzyme may be involved in regulation of ligand supply for
nuclear receptors such as the PPARs, and in shuttling fatty acids away from
esterification and triglyceride formation in the cytosol, towards oxidation (15).
Esterification and triglyceride formation require the CoA ester of fatty acids,
whereas free fatty acids and CoA esters may act as ligands for PPARs. The more
potent ligands for PPARs are identified as free fatty acids e.g. linoleic acid,
linolenic acid and arachidonic acid whereas straight chain saturated long chain
fatty acids are weaker ligands in-vitro. It was also recently shown that acyl-CoA
esters of fatty acids can also act as ligands for the PPARs (10). Notably also
HNF4a can be activated or inhibited by acyl-CoAs, depending on chain-length
and degree of saturation (14), although it is also active in the absence of
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endogenous ligand. ACOT1 hydrolyzes acyl-CoAs to the free fatty acid and CoA,
and recombinant mouse ACOT1 hydrolyzes saturated straight-chain acyl-CoAs
such as myristoyl-CoA (C14-CoA), palmitoyl-CoA (C16-CoA) and stearoyl-CoA
(C18-CoA), but is also active on unsaturated acyl-CoAs such as palmitoleoyl-CoA
(C16:1-CoA), oleoyl-CoA (C18:1-CoA) and linoleoyl-CoA (C18:2-CoA), although to a
lesser extent (30). It is therefore tempting to hypothesize that Acot1 can play a
central role in regulating long-chain acyl-CoA/free fatty acid levels, which
would in turn control intracellular levels of ligands for both the PPARa and
HNF4a. Preliminary data suggests that ACOT1 is a nucleo-cytoplasmic protein
(Lindquist et al, unpublished result) and is therefore localized in the nucleus at
the point where it could act in ligand supply for nuclear receptors. With Acot1
itself being a positive target gene of the PPARa , this could provide a self-
inducing mechanism i.e. Acot1 is upregulated by fibrates/fasting, thereby
supplying ligand for PPARa and maintaining its own upregulation. This
upregulation could in turn be elegantly counteracted via interplay between both
PPARa and the HNF4a acting directly on the Acot1 promotor. The true in-vivo
function of Acot1 however, will hopefully be evident with the production of an
Acot1 null mouse model, work that is currently underway in our laboratory.
It is not yet known if the upregulation of Acot1 in the HNF4a knockout mouse
liver is a direct result of the loss of HNF4a , or alternatively a secondary
consequence of the perturbed lipid metabolism in these animals. While Acot1 is
upregulated in the absence of HNF4a  in mouse liver, the promotor is also
slightly upregulated by HNF4a, which is a paradox. However, a similar situation
exists for the MCAD, which is upregulated in the HNF4a null mouse liver (13),
but the promotor is also activated by HNF4a (31). The expression of both Acot1
and MCAD are highly modulated in accordance with fatty acid oxidation rates,
and Acot 1 is also co-expressed in liver and kidney (19) with HNF4a, which
would allow regulation by HNF4a in these tissues. The competition experiments
performed in cells indicates that HNF4a  can repress the Acot1 promotor
activation by ligand-activated PPARa, although the mechanism behind this is
not yet understood. As both these receptors have a positive effect on the Acot1
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promotor,  one would expect that addition of activated PPARa and HNF4a may
result in a synergestic increase in promotor activity. However transcriptional
regulation by HNF4a is accomplished by interactions with various coactivators
or co-repressors, such as histone deacetylae 1 (HDAC1) (a co-repressor), and a
very recent study by Stanulovic et al showed that both HNF4a and HDAC1 are
present on an upstream enhancer element of the glutamine synthetase (GS)
promotor, which results in suppression of GS expression in liver periportal areas
(29). Therefore the competition between HNF4a and PPARa for binding to the
Acot1 DR1 is likely a complicated interplay between co-activators, co-repressors
and ligand availability.
Recent reports using DNA microarray studies have identified Acot1 induction by
several different treatments. In female rat liver and small intestine, Acot1 was
induced by dexamethasone, a rodent pregnane X receptor (PXR) agonist (32).
Treatment of rats with sesamin, a major lignin in sesame seeds known to have
cholesterol and lipid lowering activities, resulted in an approx. 100-fold
upregulation of Acot1 in rat liver, although the authors state that this
upregulation may be an over-estimation (33). However, given that Acot1 is
upregulated 90-fold in liver in response to Wy-14,643, this may not be an over-
estimation and may require further investigation. To our knowledge, this
upregulation of Acot1 at mRNA by PPARa activators is the highest identified to
date. A further study also identified Acot1 mRNA induction by a synthetic liver
X receptor (LXR) agonist in liver and brown adipose tissue in mouse (34). Thus
Acot1 is a highly regulated gene in several different tissues, and can be rapidly
regulated at mRNA and protein level under different physiological conditions.
Acot1 is a member of a gene family of acyl-CoA thioesterases, with six members
of this gene family localized in a cluster on mouse chromosome 12 D3 (19,35).
These gene products result in proteins localized in cytosol (ACOT1),
mitochondria (ACOT2) and peroxisomes (ACOT3-6). Interestingly, all members
of this gene family are targets of the PPARa, however the Acot1 shows the
highest level of induction at mRNA level by PPARa activators. Although these
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genes are located in close proximity to each other, they all have distinct promotor
regions and likely individual PPREs regulating their transcriptional level. The
human orthologue of the ACOT1 has recently been characterized and is localized
in a cluster on human chromosome 14q24.3, together with mitochondrial and
peroxisomal related genes (19,36). The promotor of the human ACOT1 contains
several DR1 elements, however we have examined the regulation of the human
ACOT1 in liver from bezafibrate treated patients using Northern blot, but no
significant upregulation was evident at mRNA level. There are large species
differences in response to fibrate treatment and rodents are very susceptible to
peroxisome proliferation, hepatomegaly and upregulation of fatty acid oxidation
enzymes in response to fibrates. In contrast, humans are not susceptible to the
above effects of fibrate treatment, although these fibrates act as very efficient
lipid lowering drugs in man (37).
In conclusion, we have identified that Acot1 is regulated by both the PPARa and
HNF4a nuclear receptors, resulting in an activation of promotor activity. In-vivo,
both the HNF4a and the PPARa are involved in the basal expression of this gene.
Acot1 is therefore regulated via a complex interplay between these nuclear
receptors and would be regulated in response to changes in ligand
concentrations of both acyl-CoAs and free fatty acids, which are in fact the
substrates/products of its own catalysis.
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Figure legends:
Fig. 1: Expression of Acot1 mRNA is regulated by fibrate treatment in mouse
liver. Total RNA was isolated from livers of wild-type (PPARa (+/+)) and
PPARa-null (PPARa (-/-)) male mice fed 0.1% Wy-14,643 for one week. The
relative mRNA levels of Acot1 were measured using Taqman Quantitative Real-
Time PCR. mRNA levels for individual animals were measured in triplicate. The
wild-type control value for one animal was set to 1. Calculations were performed
according to the DDCt method using eukaryotic 18S rRNA as an endogenous
control. n=3 ± S.D. (p<0.003, unpaired Student’s t-test).
Fig. 2: The Acot1 promotor contains a direct repeat 1.
The core consensus sequence for the direct repeat 1 (DR1) known to bind the
PPARa/RXRa heterodimer is shown (DR1 consensus), together with the 5’
flanking sequence. The putative DR1 for mouse Acot1 is shown.
Fig. 3: The Acot1 promotor is activated by PPARa/RXRa. HepG2 cells were
transfected with promotor constructs containing empty pGL3 promotor vector,
Acox1 PPRE (2 copies) (AOx-tk-Luc) and pGL3-Acot1-1861. (A) Cells were
transiently transfected with the indicated promotor vector (0.25 mg) ± PPARa
(0.25 mg) and RXRa (0.25 mg). Empty pcDNA3.1+ vector was used to keep DNA
concentrations equal in all transfections. 24 h post transfection, cells were treated
with vehicle (DMSO) or 50 mM Wy-14,643 for a further 24 h. Transfections were
carried out in triplicate wells in three or four different experiments. Luciferase
activity was normalized to b-galactosidase activity. Data shown as mean ± S.E.M
for Acox1 and Acot1 (p<0.001 for ligand activation (PPARa/RXRa + DMSO vs
PPARa/RXRa  + Wy-14,643 - Student’s t-test)) (B) Cells were transiently
transfected with the Acot1 promotor constructs pGL3-Acot1-1861 or pGL3-
Acot1D1861 (0.25 mg) ± PPARa  (0.25 mg) and RXRa  (0.25 mg). 24 h post
transfection, cells were treated with 50 mM Wy-14,643. Transfections were carried
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out in triplicate wells in three different experiments. Luciferase activity was
normalized to b-galactosidase activity. Data shown as mean ± S.E.M. (p<0.001,
unpaired Students’ t-test). Mutated bases in the DR1 are shown underlined in
italics.
Fig. 4: The Acot1 DR1 binds PPARa/RXRa in-vivo and in-vitro. (A) ChIP was
carried out on liver nuclei of PPARa wild type (+/+) and PPARa knockout (-/-)
mice treated with Wy-14,643, using a PPARa  antibody. Following
immunoprecipitation, an amplicon of 157 bp of the Acot1 promotor containing
the DR1 (located ~ -9.6 kb) was amplifed by PCR. Negative control: an amplicon
of 141 bp in the Acot1 promotor (located at ~ -1.8kb and does not contain any
DR1). (B) Electromobility shift assay (EMSA) was carried out using 1 mg of in-
vitro translated PPARa, RXRa and HNF4a. g-32P labeled probes for the Acot1
DR1 or mutated DR1 (Acot1 mut) were used. Cold probe was a 50-fold molar
excess of unlabeled probe. Supershift experiments were carried out using an
RXRa antibody (Ab). The PPARa/RXRa heterodimer is indicated by an arrow
while the supershift complexes are indicated by an arrowhead.
Fig. 5: The Acot1 promotor is regulated by HNF4a. (A) HeLa cells were
transiently transfected for 48 hours with 0.25 mg of the empty pGL3 promotor
vector, OTC-235-Luc as a positive control (28), the Acot1 promotor construct
pGL3-Acot1-157 or the mutated Acot1 promotor construct pGL3-Acot1D157,
together with HNF-4a  (0.25 mg) or pcDNA3.1+ (empty vector) (0.25 mg).
Transfections were carried out in triplicate wells in two or three different
experiments. Luciferase activity was normalized to b-galactosidase activity. Data
are shown ± S.E.M for OTC-Luc 235 (p<0.001, unpaired Students’ t-test) and ±
S.E.M. for Acot 1 (p<0.001, unpaired Students’ t-test). (B) HeLa cells were
transiently transfected with 0.25 mg of the empty pGL3 promotor vector, the
Acot1 promotor construct pGL3-Acot1-157 or the mutated Acot1 promotor
construct pGL3-Acot1D157, PPARa (0.25 mg) and RXRa (0.25 mg), plus addition
of HNF-4a (0.25 mg or 0.5 mg) or pcDNA3.1+ (empty vector) (0.25 mg or 0.5 mg).
Cells were treated with 50 mM Wy-14,643 and incubated 48 hours. Transfections
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were carried out in triplicate wells in two different experiments. Luciferase
activity was normalized to b-galactosidase activity.
Fig. 6: The Acot1 is regulated by HNF4a. (A) ChIP was carried out on liver
nuclei of HNF4a flox (F/F) and HNF4a knockout mice (HNF4a D L), using a
HNF4a antibody (K2915, Abcam). Following immunoprecipitation, an amplicon
of 157 bp of the Acot1 promotor containing the DR1 (located ~ -9.6kb upstream
of the ATG start site) was amplifed by PCR. Negative control: an amplicon of 141
bp in the Acot1 promotor (located at ~ -1.8kb and does not contain any DR1). (B)
Electromobility shift assay (EMSA) was carried out using 1 mg of in-vitro
translated HNF4a. g-32P labeled probes for the Acot1 DR1 or mutated DR1
(Acot1 mut) were used. Cold probe was a 50-fold molar excess of unlabeled
probe. Supershift experiments were carried out using an HNF4a antibody (Ab).
The HNF4a homodimer is indicated by an arrow while the supershift complex is
indicated by an arrowhead. (C) Total RNA was isolated from livers of control
male HNF4a flox (F/F)  or HNF4a knockout mice (HNF4a DL). The relative
mRNA levels of Acot1 were measured using quantitative real-time PCR and
mRNA for individual animals was measured in triplicate. The control value for
one floxed animal was set to 1. Calculation were performed according to the
DDCt method using eukaryotic 18S rRNA as an endogenous control. n=4. Data
shown as mean ± S.D. (p<0.01, unpaired Students’ t-test).
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